Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trans-activating mutations of the pseudokinase ERBB3.

Oncogene - 1 Jul 2024

Koivu Marika K A, Chakroborty Deepankar, Airenne Tomi T, Johnson Mark S, Kurppa Kari J, Elenius Klaus

Abstract excerpt

Genetic changes in the ERBB family of receptor tyrosine kinases serve as oncogenic driver events and predictive biomarkers for ERBB inhibitor drugs. ERBB3 is a pseudokinase member of the family that, although lacking a fully active kinase domain, is well known for its potent signaling activity as a heterodimeric complex with ERBB2. Previous studies have identified few transforming ERBB3 mutations while the great...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Mutation, Missense
Share to NIH 3T3 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Quinolines

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Share to Signal Transduction

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 38806620
DOI: 10.1038/s41388-024-03070-9
PMCID: PMC11245391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trans-activating mutations of the pseudokinase ERBB3.PMID 38806620Read ↗

Trans-activating mutations of the pseudokinase ERBB3Semantic proximity Read ↗

Mutations in ERBB3 drive tumorigenesis.Semantic proximity Read ↗

Activating HER3 mutations in breast cancerSemantic proximity Read ↗

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.Semantic proximity Read ↗

High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.Semantic proximity Read ↗

HER family in cancer progression: From discovery to 2020 and beyond.Semantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.Semantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.